Loading…
Based on limited metadata, this FDA Warning Letter issued to Griffo Botanicals on October 7, 2020, addresses violations related to drug products. While the specific nature of the violations cannot be determined from the available metadata (no subject line or detailed description provided), the letter indicates that the company's manufacturing, marketing, or distribution practices for drug products did not meet FDA requirements. The exact regulatory scope and specific violations remain unclear without access to the full letter text.